Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer

The cancer vaccine 105AD7 is an anti-idiotypic monoclonal antibody that mimics the tumour-associated antigen 791T/gp72 (CD55, Decay Accelerating Factor) on colorectal cancer cells. Phase I studies in patients with advanced disease confirmed that 105AD7 is non-toxic, and that T cell responses could b...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Maxwell-Armstrong, C A, Durrant, L G, Buckley, T J D, Scholefield, J H, Robins, R A, Fielding, K, Monson, J R T, Guillou, P, Calvert, H, Carmichael, J, Hardcastle, J D
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2001
Teme:
Regular Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2363670/
https://ncbi.nlm.nih.gov/pubmed/11384090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2001.1725
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items